Sangamo acquires TxCell for cell therapy

Sangamo Therapeutics, the zinc-finger gene-editing company, plans to expand its cell therapy pipeline by acquiring the French biotech firm TxCell for about $84 million. So far most cell therapies are intended to treat cancer, but TxCell is developing …